Low lipase levels as an independent marker of pancreatic cancer: a frequently neglected condition in clinical setting

Gültepe, İlhami; Başaranoğlu, Metin; Zorlu, Mehmet; Şenyiğit, Abdülhalim; Taşkale, Emine Zeynep; Atay, Kadri; Köroğlu, Emine

doi:10.5152/tjg.2016.16056

Cited by 7 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with the low serum GP2a levels in pancreatic cancer in our study, diminished levels of serum lipase have been reported as an independent marker of pancreatic cancer recently [40]. In contrast, elevated GP2 levels were found in pancreatic ductal fluid of pancreatic cancer but not of pancreatitis patients recently [41].…”

Section: Discussionsupporting

confidence: 92%

Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2

Roggenbuck

Goihl

Hanack

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2 DOI 10.1515/cclm-2016-0797 Received September 6, 2016 accepted October 10, 2016; previously published online November 12, 2016 Abstract Background: Glycoprotein 2 (GP2), the pancreatic major zymogen granule membrane glycoprotein, was reported to be elevated in acute pancreatitis in animal models. Methods: Enzyme-linked immunosorbent assays (ELISAs) were developed to evaluate human glycoprotein 2 isoform alpha (GP2a) and total GP2 (GP2t) as specific markers for acute pancreatitis in sera of 153 patients with acute pancreatitis, 26 with chronic pancreatitis, 125 with pancreatic neoplasms, 324 with non-pancreatic neoplasms, 109 patients with liver/biliary disease, 67 with gastrointestinal disease, and 101 healthy subjects. GP2a and GP2t levels were correlated with procalcitonin and C-reactive protein in 152 and 146 follow-up samples of acute pancreatitis patients, respectively.

show abstract

Section: Discussionsupporting

confidence: 92%

Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2

Roggenbuck

Goihl

Hanack

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…However, there is a scarcity of data indicating that a measurement of either lipase or amylase can be used as a good diagnostic or prognostic tool in pancreatic cancer patients. Gultepe and colleagues have recently shown that lowered lipase levels close to zero might represent a potential indicator for pancreatic cancer [ 24 ]. Ventrucci et al found a highly variable enzyme behavior with low serum lipase levels (10%) and high serum lipase levels (25%) in patients with pancreatic cancer—the authors thus concluded that pancreatic enzymes might have no added diagnostic value, neither for chronic pancreatitis nor pancreatic cancer patients [ 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, biochemical biomarkers, e.g., uric acid, were demonstrated to contain potentially important prognostic information in pancreatic cancer [ 21 , 22 ]. Both amylase and lipase have recently been investigated regarding their potential prognostic value in pancreatitis and pancreatic cancer, as well as in intraductal papillary mucinous neoplasm (IPMN) [ 23 , 24 , 25 , 26 ]. The lipase/amylase ratio (LAR) has been proposed as a possible new index that is able to distinguish acute episodes of alcoholic from non-alcoholic acute pancreatitis [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer

Stotz

Barth

Riedl

et al. 2020

Cancers

View full text Add to dashboard Cite

Pancreatic enzymes might play a pivotal role in the pathophysiology and prognosis of pancreatic cancer. The aim of this study is to investigate the lipase/amylase ratio (LAR), representing a marker previously used in the differentiation of pancreatitis, as a potential prognostic marker in pancreatic cancer. Data from 157 surgically treated patients with ductal pancreatic adenocarcinoma and 351 patients with metastatic disease were evaluated retrospectively. Cancer-specific survival (CSS) was considered the endpoint of the study. After applying Kaplan–Meier curve analysis, uni- and multivariate Cox regression models were calculated to evaluate the prognostic relevance of LAR. An elevated LAR at diagnosis of localized pancreatic cancer was significantly associated with higher CA19-9 levels (p < 0.05). In univariate analysis, we observed an increased LAR as a significant factor for lower CSS in localized pancreatic cancer patients (HR = 1.63; 95% CI = 1.12–2.36; p = 0.01), but not in metastatic patients (HR = 1.12; 95% CI = 0.87–1.43; p = 0.363). In multivariate analysis, including age, gender, tumor stage, Karnofsky Performance Status, tumor grade, administration of chemotherapy and the LAR, an increased LAR was confirmed to represent an independent prognostic factor regarding CSS (HR = 1.81; 95% CI = 1.17–2.77; p = 0.007) in localized pancreatic cancer patients. In conclusion, our study identified the LAR as an independent prognostic factor in surgically treated pancreatic cancer patients.

show abstract

“…目前, hPL 抑制剂疗法已被证实是预防和治疗肥胖以及与肥胖相关疾病的有效方法. 除此之外, hPL 也是一些胰腺疾病的生物标志物, 如慢性胰腺炎、胰腺出血和胰腺癌 [85] . 小分子荧光成像有成本低、灵敏度超高、易于操作、设计灵活以及实时响应等优点, 适合用于实时、原位监测目标酶活性.…”

Section: α-葡萄糖苷酶荧光探针unclassified

Research Progress of Near-Infrared Fluorescent Probes Based on 1,3-Dichloro-7-hydroxy-9,9-dimethyl-2(9H)-acridone (DDAO)

Ma¹,

Wu²,

Wang³

et al. 2023

Chinese Journal of Organic Chemistry

View full text Add to dashboard Cite

1,3-Dichloro-7-hydroxy-9,9-dimethyl-2(9H)-acridone (DDAO) is an excellent near-infrared fluorescent dye with near-infrared emission, low pKa (≈5.0), high water solubility and high quantum yield (Φ＝0.39), which has attracted much attention in recent years in the field of fluorescent probes. The researches prove that the fluorescent probes designed and synthesized based on this dye can work in mild aqueous solutions, and have excellent sensing performance, such as rapid reaction, high selectivity and sensitivity, low detection limit and obvious colorimetric signal change. In addition, the low cytotoxicity of this class of probes is of significant application for the detection of living cells and organisms. The research progress of fluorescent probes based on DDAO and its derivatives, mainly including the molecular design, action mechanism and application of probes in the recognition and detection of biological enzymes, reactive oxygen species, reactive nitrogen species, proteins and Pd 0 , is reviewed, and the development prospect of this type of fluorescent probes is prospected. Keywords 1,3-dichloro-7-hydroxy-9,9-dimethyl-2(9H)-acridone (DDAO); fluorescent probe; near infrared; detection 荧光探针是一种结合了分子识别和荧光技术的生物传感器, 通常由荧光团和识别基团通过连接臂以共价键的形式连接而成. 对特定的分析物或环境响应时, 探针自身的荧光性质会发生改变, 以此作为检测和识别的信号 [1][2] . 与传统的检测方法(电位法、极谱法或比色法) 相比 [3][4][5] , 荧光探针具有操作简单、选择性好、灵敏度高、检测范围广、响应速度快以及对样品损伤小等优点 [6][7] , 已经被成功应用于生物医学、生命科学及环境科学等领域 [8][9] . 荧光探针不仅可以检测阳离子和阴离子 [10][11][12] , 还可以检测活性氧 [13][14][15] 及硫化氢等小分子化合物 [16][17][18] , 近年来检测生物酶 [19] 和细菌 [20][21] 等生物活性物质的荧光探针也越来越多. 最值得一提的是, 由于部分荧光探针具有良好的生物相容性、高灵敏度、无创性、稳定的发射特性和实时成像等优点, 使得基于荧光探针的生物成像技术发展迅速, 现在已成为可视化多种生理和病理过程的有力工具 [22][23][24] . 但令人遗憾的是, 发射波长小于 600 nm 的荧光探针在进行活体荧光成像时组织穿透性差, 会产生组织损伤, 同时受到机体自发荧光的干扰,

show abstract

Low lipase levels as an independent marker of pancreatic cancer: a frequently neglected condition in clinical setting

Cited by 7 publications

References 8 publications

Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2

Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2

The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer

Research Progress of Near-Infrared Fluorescent Probes Based on 1,3-Dichloro-7-hydroxy-9,9-dimethyl-2(9H)-acridone (DDAO)

Contact Info

Product

Resources

About